| Arm . | AE . | Grade . |
|---|---|---|
| Arm A | Diarrhea | 3 |
| Arm A | Stomach pain | 3 |
| Arm A | Diarrheaa | 2 |
| Arm B | Rash maculopapular | 3 |
| Arm C | Rash maculopapularb | 3 |
| Arm . | AE . | Grade . |
|---|---|---|
| Arm A | Diarrhea | 3 |
| Arm A | Stomach pain | 3 |
| Arm A | Diarrheaa | 2 |
| Arm B | Rash maculopapular | 3 |
| Arm C | Rash maculopapularb | 3 |
aDue to persistent grade 2 diarrhea, patient had dose delay, less than 75% planned ipatasertib dose.
birAE attributed to atezolizumab.
| Arm . | AE . | Grade . |
|---|---|---|
| Arm A | Diarrhea | 3 |
| Arm A | Stomach pain | 3 |
| Arm A | Diarrheaa | 2 |
| Arm B | Rash maculopapular | 3 |
| Arm C | Rash maculopapularb | 3 |
| Arm . | AE . | Grade . |
|---|---|---|
| Arm A | Diarrhea | 3 |
| Arm A | Stomach pain | 3 |
| Arm A | Diarrheaa | 2 |
| Arm B | Rash maculopapular | 3 |
| Arm C | Rash maculopapularb | 3 |
aDue to persistent grade 2 diarrhea, patient had dose delay, less than 75% planned ipatasertib dose.
birAE attributed to atezolizumab.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
